Tango Therapeutics, Inc. announced that three abstracts have been selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, November 8-12, 2022, in Boston, Massachusetts, and online. The company is looking forward to presenting data on TNG260, a novel, highly selective CoREST inhibitor with the potential to reverse the immune evasion driven by STK11 loss-of-function mutations. STK11 mutations occur in approximately 15% of non-small cell lung cancers and render those tumors resistant to checkpoint inhibitors.

STK11 loss-of-function mutations occur in ~15% of non-small cell lung cancer and drive immune evasion, rendering STK11-mutant tumors insensitive to the immune checkpoint inhibitor therapy that significantly prolongs survival in STK11-wild type cancers. STK11 mutations also are found in ~15% of cervical cancer, 10% of carcinoma of unknown primary, 5% of breast cancer and 3% of pancreatic cancer. TNG260 is a novel small molecule inhibitor of the Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) deacetylase complex.

TNG260 is being developed to reverse immune evasion in STK11 mutated cancers, with the aim of restoring sensitivity to immune checkpoint inhibition. In preclinical studies, selective CoREST inhibition by TNG260 results in transcriptional reprogramming of STK11-mutant tumor cells, altering tumor cell cytokine secretion and markedly reducing recruitment of suppressive T cells to STK11-mutant tumors. TNG260 in combination with anti-PD1 treatment drives complete regressions in multiple syngeneic STK11-mutant xenograft models.

The Company expects to file an Investigational New Drug (IND) application for TNG260 in the first half of 2023.